专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130011409A1 Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1 有权
标题翻译：使用半乳凝素-1的移植后淋巴增殖性疾病和缺氧相关血管发生障碍的诊断，预后，监测，治疗和调节的组合物，试剂盒和方法
公开(公告)号：US20130011409A1
公开(公告)日：2013-01-10
申请号：US13509466
申请日：2010-11-12
申请人： Margaret A. Shipp , Jing Ouyang , Kunihiko Takeyama , Jeffery L. Kutok , Scott J. Rodig , Gabriel Rabinovich , Diego Omar Croci Russo , Mariana Salatino
发明人： Margaret A. Shipp , Jing Ouyang , Kunihiko Takeyama , Jeffery L. Kutok , Scott J. Rodig , Gabriel Rabinovich , Diego Omar Croci Russo , Mariana Salatino
IPC分类号： A61K39/395 , C12N15/63 , G01N33/577 , C12Q1/68 , C12N5/078 , C12N5/071 , C40B30/04 , C12N5/12 , C12N1/21 , C12N1/19 , C07K16/18 , A61P35/00 , A61P9/00 , A61K39/00 , A61K31/7088 , A61K38/02 , C07K19/00 , C07K16/46 , C12N15/13
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/34 , C07K2317/73 , C07K2317/76
摘要： The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
摘要翻译：本发明部分地基于半乳凝素-1（Gal1）在病毒相关PTLD中起作用的发现，例如与EBV相关的PTLD和缺氧相关血管生成障碍。因此，本发明涉及用于诊断，预后，监测，治疗和调节病毒相关PTLD的组合物，试剂盒和方法，例如与EBV相关的PTLD和缺氧相关血管生成障碍。

2. 发明授权

US07632660B2 Lymphoma associated molecules and uses therefor 有权
公开(公告)号：US07632660B2
公开(公告)日：2009-12-15
申请号：US11125015
申请日：2005-05-09
申请人： Margaret A. Shipp , Ricardo Aguiar , Liqun Gu , Kunihiko Takeyama
发明人： Margaret A. Shipp , Ricardo Aguiar , Liqun Gu , Kunihiko Takeyama
IPC分类号： C12P21/00 , C07K14/00 , C07H21/04
CPC分类号： C07K14/47 , A01K2217/05 , C07K2319/00
摘要： The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BBAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a BBAP gene has been introduced or disrupted. The invention still further provides isolated BBAP proteins, fusion proteins, antigenic peptides and anti-BBAP antibodies. Diagnostic methods using compositions of the invention are also provided.

3. 发明授权

US5527801A Ameliorant for blood lipid metabolism 失效
标题翻译：改善血脂代谢
公开(公告)号：US5527801A
公开(公告)日：1996-06-18
申请号：US204430
申请日：1994-03-14
申请人： Yoshinobu Masuda , Hisao Minato , Akihisa Ikeno , Kunihiko Takeyama , Kanoo Hosoki
发明人： Yoshinobu Masuda , Hisao Minato , Akihisa Ikeno , Kunihiko Takeyama , Kanoo Hosoki
IPC分类号： A61K31/495 , C07D337/12
CPC分类号： A61K31/495 , C07D337/12
摘要： The present invention is to provide an ameliorant for blood lipid metabolism which comprises as an active ingredient N-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)-4-(4-fluorophenyl)-1-piperazinebutanamide or a pharmaceutically acceptable salt thereof, more particularly, to provide a hyperlipidemia inhibitor and an atherosclerosis inhibitor.
摘要翻译： PCT No.PCT / JP92 / 01173 Sec。 371日期：1994年3月14日 102（e）1994年3月14日PCT提交1992年9月14日PCT公布。公开号WO93 / 05778 日期：1993年04月1日本发明提供一种血脂代谢改善剂，其包含作为活性成分的N-（6,11-二氢二苯并[b，e]硫杂-11-基）-4-（4- 氟苯基）-1-哌嗪丁酰胺或其药学上可接受的盐，更具体地，提供高脂血症抑制剂和动脉粥样硬化抑制剂。

4. 发明授权

US07112420B2 Lymphoma associated molecules and uses therefor 有权
公开(公告)号：US07112420B2
公开(公告)日：2006-09-26
申请号：US09957635
申请日：2001-09-19
申请人： Margaret A. Shipp , Ricardo Aguiar , Liqun Gu , Kunihiko Takeyama
发明人： Margaret A. Shipp , Ricardo Aguiar , Liqun Gu , Kunihiko Takeyama
IPC分类号： C12N15/00 , C12N15/85 , C12N15/63 , C07H21/04
CPC分类号： C07K14/47 , A01K2217/05 , C07K2319/00
摘要： The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BBAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a BBAP gene has been introduced or disrupted. The invention still further provides isolated BBAP proteins, fusion proteins, antigenic peptides and anti-BBAP antibodies. Diagnostic methods using compositions of the invention are also provided.

5. 发明授权

US5338940A Apparatus for ion implantation including contactless cooling and beam current measurement means 失效
标题翻译：用于离子注入的装置，包括非接触式冷却和束电流测量装置
公开(公告)号：US5338940A
公开(公告)日：1994-08-16
申请号：US917208
申请日：1992-07-21
申请人： Kunihiko Takeyama
发明人： Kunihiko Takeyama
IPC分类号： H01J37/317 , H01J37/30 , G21K5/08
CPC分类号： H01J37/3171 , H01J2237/2001 , H01J2237/20257 , H01J2237/31703
摘要： Wafer disk holds wafers in position by centrifugal force and its rotating shaft is supported by a bearing capable of magnetic levitation that has a thrust bearing and radial bearings. An annular groove providing a heat radiating zone is formed under the wafer receiving faces of the wafer disk. A cooling plate cooled to a temperature not exceeding the temperature of liquid nitrogen is inserted into the groove in a contactless manner so that the wafer disk is cooled by heat radiation. In the absence of any area of physical contact in the mechanisms for axially supporting and cooling the wafer disk, ions can be implanted in low dose into wafers on the fast rotating disk while improving the quality of wafers after implantation. Further, no triboelectricity will develop, thereby contributing to an improvement in the precision of ion beam current measurement.
摘要翻译：晶圆盘通过离心力将晶片保持在适当位置，其旋转轴由具有推力轴承和径向轴承的磁悬浮轴承支撑。在晶片盘的晶片接收面的下方形成设置散热区的环状槽。将冷却至不超过液氮温度的冷却板以非接触的方式插入槽中，从而通过热辐射冷却晶片盘。在用于轴向支撑和冷却晶片盘的机构中没有任何物理接触区域的情况下，可以将离子以低剂量注入快速旋转盘上的晶片中，同时改善植入后晶片的质量。此外，不会产生摩擦电，从而有助于提高离子束电流测量的精度。

6. 发明授权

US4248883A 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds 失效
标题翻译： 1-（3-巯基-2-甲基丙酰基）脯氨酰氨基酸衍生物及其盐，其制备方法和含有这些化合物的药物组合物
公开(公告)号：US4248883A
公开(公告)日：1981-02-03
申请号：US53206
申请日：1979-06-29
申请人： Tadahiro Sawayama , Hiroaki Kinugasa , Haruki Nishimura , Kunihiko Takeyama , Kanoo Hosoki
发明人： Tadahiro Sawayama , Hiroaki Kinugasa , Haruki Nishimura , Kunihiko Takeyama , Kanoo Hosoki
IPC分类号： A61K31/40 , A61P43/00 , C07D207/10 , C07D207/16 , C07K5/06 , C07K5/078 , C07K14/81 , C07D207/09
CPC分类号： C07K5/06165 , C07C327/00 , C07D207/16
摘要： 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives of the formula ##STR1## wherein R represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a substituted phenyl-lower alkyl group, R.sub.1 represents a hydrogen atom, R.sub.4 CO--, R.sub.5 S--, or ##STR2## R.sub.2 represents a hydrogen atom or a lower alkyl group, R.sub.3 represents a hydrogen atom, a phenyl group, a lower alkyl group, or a substituted lower alkyl group, or R.sub.2 and R.sub.3 form a heterocyclic ring together with the nitrogen and carbon atoms to which they are respectively bonded; salts of these compounds; compositions comprising these compounds or salts; and processes for preparing these compounds or salts. These compounds and salts have excellent antihypertensive activity.
摘要翻译：式（I）的1-（3-巯基-2-甲基丙酰基）脯氨酰氨基酸衍生物，其中R表示氢原子，低级烷基，苯基 - 低级烷基或取代的苯基 - 低级烷基，R 1表示氢原子，R4CO-，R5S-或R2表示氢原子或低级烷基，R3表示氢原子，苯基，低级烷基或取代的低级烷基，或R2和 R3与它们分别键合的氮和碳原子一起形成杂环; 这些化合物的盐; 包含这些化合物或盐的组合物; 以及制备这些化合物或盐的方法。这些化合物和盐具有优异的抗高血压活性。

7. 发明授权

US08968740B2 Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 有权
标题翻译：使用半乳凝素-1的移植后淋巴增殖性疾病和缺氧相关血管生成障碍的诊断，预后，监测，治疗和调节的组合物，试剂盒和方法
公开(公告)号：US08968740B2
公开(公告)日：2015-03-03
申请号：US13509466
申请日：2010-11-12
申请人： Margaret A. Shipp , Jing Ouyang , Kunihiko Takeyama , Jeffery L. Kutok , Scott J. Rodig , Gabriel Rabinovich , Diego Omar Croci Russo , Mariana Salatino
发明人： Margaret A. Shipp , Jing Ouyang , Kunihiko Takeyama , Jeffery L. Kutok , Scott J. Rodig , Gabriel Rabinovich , Diego Omar Croci Russo , Mariana Salatino
IPC分类号： A61K39/395 , C12N5/20 , C07K16/18 , C07K16/22 , A61K39/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/34 , C07K2317/73 , C07K2317/76
摘要： The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
摘要翻译：本发明部分地基于半乳凝素-1（Gal1）在病毒相关PTLD中起作用的发现，例如与EBV相关的PTLD和缺氧相关血管生成障碍。因此，本发明涉及用于诊断，预后，监测，治疗和调节病毒相关PTLD的组合物，试剂盒和方法，例如与EBV相关的PTLD和缺氧相关血管生成障碍。

8. 发明申请

US20070259342A1 Lymphoma associated molecules and uses therefor 有权
标题翻译：淋巴瘤相关分子及其用途
公开(公告)号：US20070259342A1
公开(公告)日：2007-11-08
申请号：US11125015
申请日：2005-05-09
申请人： Margaret Shipp , Ricardo Aguiar , Liqun Gu , Kunihiko Takeyama
发明人： Margaret Shipp , Ricardo Aguiar , Liqun Gu , Kunihiko Takeyama
IPC分类号： C12Q1/68 , C07H21/04 , C07K14/00 , C07K16/18 , G01N33/53 , C12N15/00 , C12N5/06 , C12P1/04
CPC分类号： C07K14/47 , A01K2217/05 , C07K2319/00
摘要： The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BBAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a BBAP gene has been introduced or disrupted. The invention still further provides isolated BBAP proteins, fusion proteins, antigenic peptides and anti-BBAP antibodies. Diagnostic methods using compositions of the invention are also provided.
摘要翻译：本发明提供分离的核酸分子，称为BBAP核酸分子，其编码与非霍奇金淋巴瘤差异表达的BAL分子相互作用或结合的蛋白质。本发明还提供反义核酸分子，含有BBAP核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及引入或破坏了BBAP基因的非人转基因动物。本发明还进一步提供了分离的BBAP蛋白，融合蛋白，抗原肽和抗BBAP抗体。还提供了使用本发明组合物的诊断方法。

9. 发明授权

US4826814A Tripeptide derivatives 失效
公开(公告)号：US4826814A
公开(公告)日：1989-05-02
申请号：US046189
申请日：1987-05-05
申请人： Tadahiro Sawayama , Masatoshi Tsukamoto , Takashi Sasagawa , Kazuya Nishimura , Kanoo Hosoki , Kunihiko Takeyama
发明人： Tadahiro Sawayama , Masatoshi Tsukamoto , Takashi Sasagawa , Kazuya Nishimura , Kanoo Hosoki , Kunihiko Takeyama
IPC分类号： A61K38/00 , A61K38/05 , A61K38/06 , A61K38/55 , A61P9/00 , A61P9/12 , A61P43/00 , C07K1/02 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/068 , C07K5/08 , C07K14/81 , A61K37/43
CPC分类号： C07K5/06086 , C07K5/0215 , A61K38/00
摘要： There are provided tripeptide compounds represented by the following formula ##STR1## wherein R.sub.1 represents a C.sub.1-10 alkyl group, a C.sub.4-7 cycloalkyl or C.sub.5-7 cycloalkyl-lower alkyl group, a phenyl or phenyl-lower alkyl group in which the benzene ring may optionally be substituted by a substituent selected from halogen, lower alkyl, lower alkoxy, phenyl, methylenedioxy, ethylenedioxy, amino, di(lower alkyl)amino and hydroxy, a naphthyl or naphthyl-lower alkyl group in which the naphthalene ring may optionally be substituted by a substituent selected from halogen, lower alkyl, lower alkoxy and hydroxy, a heterocyclic or heterocyclic-lower alkyl group in which the heterocycle is a saturated or unsaturated 5- or 6-membered ring containing a nitrogen, oxygen or sulfur atom as the hetero atom, and may optionally be substituted by a substituent selected from halogen, lower alkyl, lower alkoxy, amino, di(lower alkyl)amino, hydroxy, oxo and saturated 5- or 6-membered nitrogen-containing heterocyclic group, and further may optionally be fused to a benzene ring, or an imidazolylvinyl group; R.sub.2 represents a hydrogen atom, a C.sub.1-10 alkyl group or a benzyl group; R.sub.3 represents a group of the formula ##STR2## represents a benzene, cyclopentane or cyclohexane ring, R.sub.4 represents a hydrogen atom, a C.sub.1-10 alkyl group or a benzyl group, p is 0 or 1, q is 1, 2, or 3, and X represents a phenyl group which may optionally be substituted by a substituent selected from halogen, lower alkoxy and hydroxy, a C.sub.4-8 cycloalkyl group, or a C.sub.5-7 cycloalkyl group which is fused to a benzene, and Y represents a hydrogen atom or a lower alkyl group, or X and Y, together with the nitrogen and carbon atoms to which they are bonded, forms a 5- or 6-membered heterocycle which may contain a nitrogen, oxygen or sulfur atom,W represents a single bond, --O-- or --NH--, T represents a single bond, ##STR3## and m is 2 or 3, or salts thereof and processes for production thereof. The compounds are useful as antihypertensive agents.

10. 发明授权

US3985875A .omega.-(N-acylamino)alkylphosphoryl ethanolamines, pharmaceutical compositions containing them, and their uses 失效
标题翻译： {107-（N-酰基氨基）烷基磷酰基乙醇胺，含有它们的药物组合物及其用途
公开(公告)号：US3985875A
公开(公告)日：1976-10-12
申请号：US537601
申请日：1974-12-30
申请人： Kouji Hayashi , Masahisa Hashimoto , Kiyoshi Nakamura , Masanao Shimizu , Naonobu Hatano , Kunihiko Takeyama
发明人： Kouji Hayashi , Masahisa Hashimoto , Kiyoshi Nakamura , Masanao Shimizu , Naonobu Hatano , Kunihiko Takeyama
IPC分类号： C07F9/09 , A01N9/36
CPC分类号： C07F9/091 , Y02P20/55 , Y10S530/86
摘要： New .omega.-(N-acylamino)alkylphosphoryl ethanolamines and their pharmaceutically acceptable acid addition salts have superior renin-inhibitory activities, antihypertensive activities and cholesterol-lowering activities. The .omega.-(N-acylamino)alkylphosphoryl ethanolamines are prepared by (1) reacting an .omega.-(N-acylamino) alkanol with a 2-(N-substituted amino)ethyl phosphate or its derivative, hydrolyzing the resulting product or splitting off the phosphoric acid-protective group of the resulting product thereby to form an .omega.-(N-acylamino) alkyl 2-(N-substituted amino) ethyl phosphate, and splitting off the amino-protective groups of the resulting phosphate, or (2) reacting an .omega.-(N-acylamino) alkanol with a phosphorus oxyhalide, reacting the resulting .omega.-(N-acylamino)alkyl dichlorophosphate with a 2-(N-substituted amino) ethanol, hydrolyzing the reaction product to form an .omega.-(N-acylamino) alkyl 2-(N-substituted)ethyl phosphate, and splitting off the amino-protective groups of said phosphate.
摘要翻译：新的ω-（N-酰基氨基）烷基磷酰基乙醇胺及其药学上可接受的酸加成盐具有优异的肾素抑制活性，降压活性和降胆固醇活性。 ω-（N-酰氨基）烷基磷酰基乙醇胺通过以下步骤制备：（1）使ω-（N-酰氨基）链烷醇与2-（N-取代氨基）乙基磷酸酯或其衍生物反应，水解得到的产物或将得到产物的磷酸保护基，从而形成2-（N-取代氨基）乙基磷酸的ω-（N-酰基氨基）烷基酯，并分离得到的磷酸酯的氨基保护基，或（2）使将具有卤代磷酸酯的ω-（N-酰基氨基）链烷醇与所得的ω-（N-酰基氨基）烷基二氯磷酸酯与2-（N-取代的氨基）乙醇反应，水解反应产物以形成ω-（N- 酰基氨基）烷基2-（N-取代）乙基磷酸酯，并分离出所述磷酸酯的氨基保护基团。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式